UNSPSC 51172328: Sugammadex

This classification denotes a protective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 361LPM2T56. European Medicines Agency schedules Sugammadex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26695. Sugammadex generally arises in the molecular formula C72H112O48S8. The term SUGAMMADEX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations schedule sugammadex under HS 29329985 and SITC 51569.

UNSPSC 51172328 Sugammadex is a Commodity code that state and local governments use to tag pharmaceutical and medical supply procurements, but recent solicitation activity under this code does not reflect the nominal scope. Collin County Community Supervision and Corrections Department's RFP 2026-327, the only recent opportunity tagged to this code, solicits offender specimen collection and drug testing services—laboratory analysis, immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative testing methodologies including oral fluid and hair testing. The work is fundamentally a service contract for testing operations and staffing at two collection sites in Plano and McKinney, not a pharmaceutical supply procurement. The issuing body is a county criminal-justice department operating under Texas Department of Criminal Justice funding, a use case that does not align with the code's pharmaceutical focus.

Collin County's RFP 2026-327 represents the only recent opportunity found under this code. The county seeks an RFP response with proposals due July 23, 2026, for an estimated contract value of $600,000 covering approximately 25,031 annual tests (five-panel and six-panel screens with ancillary testing) across a two-year initial term with three optional one-year renewals not to exceed five years total. The successful vendor must maintain lab certification from SAMHSA, TX DPS, or CAP and submit per-test pricing across three service models: screening only, confirmation after screening, and screening with automatic confirmation of positives. Pricing must include freight, delivery, insurance, and staffing with no additional surcharges; price reductions are required if the vendor offers lower rates elsewhere, with redetermination limited to annual anniversaries capped at 3.0 percent increases based on medical Consumer Price Index. The mismatch between the code's pharmaceutical nomenclature and the actual work being procured suggests this code shows little relevant recent activity for state and local vendors in the pharmaceutical supply space.